

Are the things we can measure useful?
Senescence Burden

Miranda Orr, PhD

Assistant Professor




Sticht Center for Healthy Aging and
Alzheimer's Prevention

Research Health Scientist




W.G. Hefner
Veterans
Medical
Center

Cellular senescence: initially discovered as a limited replicative capacity *in vitro*.



Dr. Leonard Hayflick, UCSF
Past President: GSA
Founding Member of the Council of the NIA


Cellular senescence: initially discovered as a limited replicative capacity *in vitro*.



1961. Limited replicative capacity of human cells in culture: aging at the cellular level, “Cellular Senescence”. PMID: 13905658

Dr. Leonard Hayflick, UCSF
Past President: GSA
Founding Member of the Council of the NIA

Cellular senescence biomarker discovery *in vitro* has lead to their identification *in vivo*.



Biomarkers *In Vitro*.

1995. SA β -gal¹.

1996. *CDKN2A*/p16^{INK4a} regulates cell cycle arrest².

2008. Senescence associated secretory phenotype “SASP”³.

2013. Senescence spread⁴.

Senescence *In Vivo*

2002. Detected in human atherogenic plaques⁵.

2006. Detected in aged primate skin⁶.



2011. Clearing senescent cells ameliorates progeroid phenotypes⁷.

2016. Clearing senescent cells extends healthspan and lifespan⁸.

2016-Present: Senescent cell clearance head-to-tail...

¹Dimri *et al*; (7568133); ²Alcorta *et al* (8943005); ³Coppe *et al* (19053174); ⁴Acosta *et al* (23770676); ⁵Minamino *et al* (11927518); ⁶Herbig *et al* (16456035); ⁷Baker *et al* (22048312); ⁸Baker *et al* (26840489).

Senescent cells have been detected in tissues throughout the body, drug discovery and trials are underway.



Zhu Y., et al., (2015) *Aging Cell*. PMID: 25754370

Justice J., et al., (2019) *J Gerontol A Biol Sci Med Sci*. PMID: 30616998

Table 1 | Selected biotech companies focused on senolytics

Company (year founded)	Business focus/technology
1E Therapeutics (2020)	Antisense oligonucleotide-based senolytics
Atropos Therapeutics (2018)	Targeting transition between quiescence and senescence (senescence after growth arrest, or SAGA)
Cleara Biotech (2018)	Targeting FOXO4 to release proapoptotic p53
Deciduous Therapeutics (2018)	Activating immune cells to clear senescent cells
Dialectic Therapeutics (2018)	Systemic delivery of senolytic agents using proteolysis-targeting chimeras (PROTACs)
Dorian Therapeutics (2018)	Targeting USP16, a deubiquitination enzyme, to reverse senescence
Eternans (2017)	FOXO4-binding peptide
FoxBio (2018)	Targeting p53/FOXO4 prosurvival pathways in senescent cells
Genome Protection (2018)	Stimulating innate immunity to eradicate genome-compromised cells
Geras Bio (2020)	SASP inhibitors
Insilico Medicine/ Taisho (2020)	AI target identification and generation/validation
NRTK Biosciences (2020)	Synthetic optimization of approved drugs and supplements
Numeric Biotech (2017)	Selective targeting of FOXO4-p53
Oisín Biotechnologies (2014)	Gene therapy with caspase-9 activated in p16-positive cells
Oncosence (2019)	Monoclonal antibodies targeting tumor cells after inducing them to senescence
OneSkin (2016)	Peptide that modulates senescence-related signaling pathways and enhances DNA repair
Recursion Pharma (2013)	AI drug discovery platform
Rejuversen (2020)	Antibody against PD-L2 that promotes immune-mediated clearance of senescent cancer cells
Rubedo Life Sciences (2018)	Small-molecule senolytics
Senisca (2020)	Antisense oligonucleotides against splicing factors
Senolytic Therapeutics (2017)	Senolytic and senomorphic drugs to treat fibrosis
SIWA Therapeutics (2006)	Antibody against glycation surface molecule
Unity Biotechnology (2011)	Targeting various senescence-related proteins (Bcl-xL)

Paez-Ribes et. al. (2019) *EMBO Mol Med*. PMID: 31746100

Dolgin E. (2020) *Nat Biotechnol*. PMID: 33184478

Single senescence biomarkers may have cell type biases and have highlighted the need for multi-analyte approaches.

PMID: 33799628

PMID: 33671362

- **Neurons**

- p21 PMID: 22882466
- NFT-transcriptome PMID: 30126037
- SA β -gal PMID: 31636448
- p21 PMID: 31543366
- Transcriptome (p19 + NFTs) *In Press*

Jurk D *et al.*, (2012) *Aging Cell*
Musil...OrrME, (2018) *Aging Cell*
Chow HM *et al.*, (2019) *Nat. Neurosci.*
Riessland M *et al.*, (2019) *Cell Stem Cell*
Dehkordi...OrrME (2021) *Nature Aging*

- **Astrocytes**

- p16 PMID: 22984612
- Lamin B1 PMID: 29386135

Bhat R *et al.*, (2012) *PLoS One*
Chinta SJ *et al.*, (2018) *Cell Reports*

- **Microglia**

- p16 PMID: 30232451
- p16 PMID: 33470505
- SA β -gal, SASP, MMP3 PMID: 34669475

Bussian TJ *et al.*, (2018) *Nature*
Ogrodnik, M. *et al.*, (2021) *Aging Cell*
Brelstaff *et al.*, (2021) *Sci. Adv.*

- **Oligodendrocyte precursor cells**

- p16 PMID: 30936558
- p16 PMID: 33470505


Zhang P *et al.*, (2019) *Nat. Neurosci.*
Ogrodnik, M. *et al.*, (2021) *Aging Cell*

- **Endothelial cells**

- SASP PMID: 33041998


Bryant AG *et al.*, (2020) *Front Neurol*

We observed cell-type heterogeneity using single marker genes as surrogates for “senescence”.




Mathys *et. al.*, 2019. PMID: 31042697

Zhou *et. al.*, 2020. PMID: 31932797




Gorgoulis V *et. al.*, 2019 PMID: 31675495



Dr. Habil Zare &
Shiva K. Dehkordi, UTHSA


We used a bioinformatic approach to included multiple genes, each set representing distinct aspects of cellular senescence.

snRNASeq



~140,000 Cells
76 brains


- Mathys *et. al.*, 2019
• PMID: 31042697
Zhou *et. al.*, 2020
• PMID: 31932797



What are these cell types?


Excitatory neurons are the only cell type that are represented in all three eigengenes.

SIP: Initiating




Cell Types	Cell Numbers		log10(p-value)
	Normal	Senescent	
Ast	3,391	1	~0
End	121	0	0
Ex	33,734	1,242	-2019
In	9,088	108	~0
Mic	1,920	0	0
Oli	18,235	0	0
Opc	2,627	0	0
Per	167	0	0
Total	69283	1351	

Target validation using RNAscope, immunohistochemistry and immunofluorescence indicate p19-expressing neurons have tau neuropathology.




RNAscope




Dr. Rachel Bennett & Benjamin Woost, MGH/Harvard

p19 Histology



Eric S. Orkin, UTHSA

These data and approaches open new areas of research with opportunities for major advances.




- Once senescent cells are identified, determine if they have functional consequences in people.
 - Cognitive resiliency vs dementia.
 - Clearance in clinical trials.
- Identify peripheral biomarkers unique and specific to distinct senescent cell type.
- Use biomarkers to develop *in vivo* imaging techniques.
- Understand mechanisms governing cellular senescence in post mitotic cells.


Major gaps in the field with opportunities for research.

The Common Fund's Cellular Senescence Network (SenNet) Program

Vision: To identify and functionally characterize the heterogeneity of senescent cells across multiple tissues in human health and lifespan at single cell resolution.



A Blueprint for Characterizing Senescence. Roy *et al.* *Cell*. 2020



Acknowledgements



- Timothy Orr
- Emma Bennett
- Eric Sah
- Mohamed Ahmidouch
- Dr. Suzanne Craft
- Abigail O'Connell
- Karen Gagnon
- Eric Fisher
- Eric Vail



- Bin Zhang



- Dr. C. Dirk Keene



- Dr. Habil Zare
- Shiva Kazempour
- Dr. Jamie Walker
- Dr. Mitzi Gonzales
- Dr. Sudha Seshadri
- Dr. Nick Musi
- Dr. Valentina Garbarino
- Dr. Tiffany Kautz



- Dr. Jim Kirkland
- Dr. Ron Petersen
- Dr. Tamara Tchkonja



- Dr. Rachel Bennett
- Benjamin Woost

Orr Lab is Recruiting!
morr@wakehealth.edu



NEW VISION
RESEARCH

Averill
Family



Alzheimer's
Drug Discovery
Foundation



Wake Forest®
School of Medicine

Clinical and Translational
Science Institute



National Institute of
Neurological Disorders
and Stroke



OAIC National Coordinating Center
Claude D Pepper Older Americans Independence Centers